Subscribe to Newsletter
Subspecialties Oncology, Genetics and epigenetics, Biochemistry and molecular biology, Cytology, Omics

In Pursuit of Immortality

How do human cells become immortal? Despite the important implications for cancer development, the process is not well understood. Now, a research team based in the Berkeley Lab, US, have developed a new method to create and study immortal human mammary epithelial cells (IHMECs). It is already possible to do this but the oncogenic agents used to create the cells result in multiple genomic errors, meaning the cells are not accurate models of cancer etiology. The new method generates cells with normal, stable genomes, providing a more accurate model for studying the process in the same way it actually occurs in human cancers; while human cancer tissue may contain many genomic alterations, only a small number of these are thought to play a role in disease development.

0314-206-main

This is the culmination of over 30 years of work for Berkeley researcher Martha Stampfer, lead author of the associated paper (1). “When I started this work, I was fascinated by the observation that rodent-derived cultures from both normal and tumor tissues could spontaneously immortalize in culture, but in humans, it only occurred in cells derived from tumors.

I’ve been chasing the question ever since. Understanding the molecular mechanisms, along with a reproducible method, could facilitate identification of agents that might prevent this process, and thus halt malignant progression,” she says.

It is believed that immortalization is mainly due to the upregulation of telomerase, the enzyme responsible for maintaining the telomeric ends of chromosomes, but very little is known about how human epithelial cells reactivate telomerase during cancer development in vivo. Creating the immortal cells involved overcoming two senescence barriers; using C-Myc to reactive the enzyme which maintains telomerase and allow division to continue, and using small hairpin RNA to silence the tumor suppressor p16 – a straightforward and reproducible method.

Studying cells created in this manner could provide researchers with an invaluable tool for analyzing the underpinnings of immortality and potentially developing new approaches to cancer therapy. The Berkeley team intends to continue unravelling the mysteries of immortality, as Stampfer explains, “We are currently examining the molecular changes that occur during the process. Several molecules with observed changes in expression are now being studied, and will be tested for to see if they are necessary to attain or maintain immortality. The goal would be to identify therapeutics that could prevent immortalization in pre-malignant cells.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. J.C. Garbe et al., “Immortalization of Normal Human Mammary Epithelial Cells in Two Steps by Direct Targeting of Senescence Barriers Does Not Require Gross Genomic Alterations”, Cell Cycle, 13, [epub ahead of print] (2014).
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Application Notes
Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

| Contributed by Agilent

Comprehensive Genomic Profiling with SureSelect Cancer CGP Assay

| Contributed by Agilent

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register